Joshua M. Cohen

Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial

Michel D. Ferrari, Hans‐Christoph Diener, Xiaoping Ning et al. · The Lancet · 2019 · 434 citations

Pharmacy, Pharmacology, Pharmacotherapy +14

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

Robert L. Coleman, Domenica Lorusso, Christine Gennigens et al. · The Lancet Oncology · 2021 · 394 citations

Medicine, Oncology, Pharmacotherapy +13

Long-term safety, tolerability, and efficacy of fremanezumab in migraine

Peter J. Goadsby, Stephen D. Silberstein, Paul Yeung et al. · Neurology · 2020 · 177 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +16

The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study

Stephen D. Silberstein, Joshua M. Cohen, Michael J. Seminerio et al. · The Journal of Headache and Pain · 2020 · 129 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Health care Resource Utilization and Migraine Disability Along the Migraine Continuum Among Patients Treated for Migraine

Stephen D. Silberstein, Lulu Lee, Kavita Gandhi et al. · Headache The Journal of Head and Face Pain · 2018 · 102 citations

Pharmacy, Neurology, Pharmacoeconomics +17